Clinical trial · Interventional
Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies
Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging in Patients Undergoing Selective Internal Radiation Therapy for Hepatic Malignancies
NCT04332419CI-TRIAL-00059222completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the results of positron emission tomography/computer tomography (PET/CT) to positron emission tomography/magnetic resonance imaging (PET/MRI) to help determine any added advantage of one over the other in relation to a tumor which might assist in further management plans.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Device | — | UNRESOLVED |
| PET/MR | Device | — | UNRESOLVED |
| SIRT with Y-90 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET/CT & PET/MR
- description
- One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
- interventionNames
- Device: PET/CT
- Device: PET/MR
- Radiation: SIRT with Y-90
Primary outcomes (1)
- measure
- Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues
- timeFrame
- Post-op day 0, 1 hour apart
- description
- RDC between the two imaging modalities for post-Y-90 Radioembolization (RE) absorbed doses (Gy) in the liver tumor tissues The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient has a liver malignancy and is scheduled for SIRT with Y-90; AND * The patient is an adult, self-competent, and able to provide informed consent to participate in the study Exclusion Criteria: * The patient loses competence, has a condition that questions their ability to provide informed consent independently (e.g. cannot communicate in English), or withdraws consent to participate within any time in the study period; OR * The patient is not eligible to undergo MRI due to the presence of metal devices or implants in their body; OR * Both imaging modalities cannot take place within 6 hours after Y-90 RE; OR * Both imaging modalities cannot take place within 1 hour apart from each other
References
Publications (0)
Data not yet available
No reference posted for this study.